^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Colorectal Adenocarcinoma

Related cancers:
9h
Claudin18.2 expression and its clinicopathological feature in adenocarcinoma from various parts. (PubMed, J Clin Pathol)
Our results suggest claudin18.2 might be a potential biomarker for targeted therapy on lung mucinous adenocarcinoma, cholangiocarcinoma, colorectal mucinous adenocarcinoma and gastric-type cervical adenocarcinoma.
Journal
|
CLDN18 (Claudin 18)
1d
Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD. (PubMed, J Transl Med)
Together, our findings establish the immunogenicity and therapeutic potential of mutant MUC family-derived neoantigens. Through combining the tools of TSNAdb and DAI, a group of novel MUCmut neoantigens were identified as potential targets for immunotherapy.
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • MUC16 (Mucin 16, Cell Surface Associated) • MUC4 (Mucin 4, Cell Surface Associated) • MUC13 (Mucin 13) • MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming) • MUC2 (Mucin 2) • MUC20 (Mucin 20 Cell Surface Associated) • MUC17 (Mucin 17) • MUC6 (Mucin 6)
|
TMB-H • MUC16 mutation • MUC5B mutation
1d
Association between microsatellite status and characteristics and outcomes of early-onset compared to late-onset rectal cancer. (PubMed, Int J Colorectal Dis)
In both age groups, MSI-H rectal cancers were more often mucinous and poorly differentiated carcinomas and had pT3-4 stage more often than MSS cancers. MSI-H rectal cancers tend to present less often with distant metastases and nodal involvement than MSS cancers only in early-onset, but not in late-onset rectal cancers. The association between MSI status and survival was not notable in this study, whether in the early-onset or late-onset groups.
Journal
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
1d
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=381, Recruiting, Hutchmed | Trial completion date: Sep 2023 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Dec 2025
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IFNA1 (Interferon Alpha 1)
|
PD-L1 expression • MSI-H/dMMR • ROS1 fusion • ALK-ROS1 fusion
|
Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
1d
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer (clinicaltrials.gov)
P2, N=50, Not yet recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2027 --> Apr 2028 | Initiation date: Jan 2024 --> Jan 2025 | Trial primary completion date: Apr 2025 --> Apr 2026
Trial completion date • Trial initiation date • Trial primary completion date • Tumor mutational burden
|
MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
|
MSI-H/dMMR
|
Libtayo (cemiplimab-rwlc)
2d
Tumoricidal properties of thymoquinone on human colorectal adenocarcinoma cells via the modulation of autophagy. (PubMed, BMC Complement Med Ther)
Here, we monitored the effects of Thymoquinone (TQ) on autophagy via mitochondrial function after modulation of the Wnt/β-catenin signaling pathway.Human colorectal adenocarcinoma HT-29 cells were treated with TQ (60 µM) and 15 µM Wnt3a inhibitor (LGK974) for 48 h...TQ can increase intracellular accumulation of Rhodamine 123, indicating the inhibition of efflux mechanisms in cancer cells. Along with these changes, the migration of cells was also reduced (p < 0.05).TQ is a potential phytocompound to alter the dynamic growth of human colorectal HT-29 cells via the modulation of autophagy, and mitophagy-related mechanisms.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • AXIN1 (Axin 1) • BECN1 (Beclin 1) • CDH5 (Cadherin 5) • PINK1 (PTEN Induced Kinase 1)
|
MYC expression • CDH1 expression
|
WNT974
3d
Genistein Enhances TRAIL-Mediated Apoptosis Through the Inhibition of XIAP and DcR1 in Colon Carcinoma Cells Treated with 5-Fluorouracil. (PubMed, Turk J Pharm Sci)
According to our findings, genistein, 5-fluorouracil, and TRAIL had synergistic apoptotic effects because of DR5 upregulation, ROS production, and DNA damage, which were mediated by increased caspase-8, and -9 activity and decreased MMP. The applied combinations of these compounds may contribute to the resistance problem that may occur in treating colorectal cancer, with a decrease in DcR1 and XIAP genes.
Journal
|
CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • XIAP (X-Linked Inhibitor Of Apoptosis) • ANXA5 (Annexin A5) • TNFRSF10C (TNF Receptor Superfamily Member 10c)
|
5-fluorouracil
3d
New trial
3d
Trial primary completion date • Metastases • Immune cell
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS wild-type
3d
CIFRA: Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (clinicaltrials.gov)
P2, N=34, Recruiting, National Cancer Institute, Naples | Trial completion date: Jan 2024 --> May 2024 | Trial primary completion date: Jan 2024 --> May 2023
Trial completion date • Trial primary completion date • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • GZMB (Granzyme B) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • CD86 (CD86 Molecule)
|
KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression
|
Erbitux (cetuximab) • 5-fluorouracil • irinotecan
3d
A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer (clinicaltrials.gov)
P2, N=255, Active, not recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting --> Active, not recruiting | Trial completion date: Jun 2023 --> Jun 2025
Enrollment closed • Trial completion date • Metastases
|
capecitabine • oxaliplatin
4d
SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer (clinicaltrials.gov)
P2, N=13, Completed, Providence Health & Services | Active, not recruiting --> Completed
Trial completion
|
oxaliplatin • Lonsurf (trifluridine/tipiracil)
4d
Enrollment open • Combination therapy • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF V600E • BRAF V600 • BRAF wild-type
|
Erbitux (cetuximab) • Braftovi (encorafenib) • ulixertinib (BVD-523)
5d
CDK12 is a potential biomarker for diagnosis, prognosis and immunomodulation in pan-cancer. (PubMed, Sci Rep)
These findings establish CDK12 as a significant biological indicator of cancer diagnosis, prognosis, and immunotherapeutic targeting. Early surveillance and employment of CDK12 inhibitors, along with concomitant immunotherapy interventions, may enhance the clinical outcomes of cancer patients.
Journal • IO biomarker • Pan tumor • Immunomodulating
|
CDK12 (Cyclin dependent kinase 12)
|
CDK12 mutation
6d
Cuproptosis-Related Gene FDX1 Suppresses the Growth and Progression of Colorectal Cancer by Retarding EMT Progress. (PubMed, Biochem Genet)
In conclusion, FDX1 inhibited the growth and progression of CRC by inhibiting EMT progress. This discovery hinted that FDX1 may act as an effective candidate for CRC treatment.
Journal
|
CDH1 (Cadherin 1) • EGF (Epidermal growth factor) • CDH2 (Cadherin 2) • TWIST1 (Twist Family BHLH Transcription Factor 1) • TJP1 (Tight Junction Protein 1) • FDX1 (Ferredoxin 1)
7d
Postbiotics of Lacticaseibacillus paracasei CECT 9610 and Lactiplantibacillus plantarum CECT 9608 attenuates store-operated calcium entry and FAK phosphorylation in colorectal cancer cells. (PubMed, Mol Oncol)
Cell treatment with the Orai1 inhibitor synta-66 attenuates SOCE and prevents any further effect of Lacticaseibacillus paracasei and Lactiplantibacillus plantarum postbiotics. Together, our results indicate for the first time that Lacticaseibacillus paracasei and Lactiplantibacillus plantarum postbiotics selectively exert negative effects on Ca2+ influx through SOCE in colorectal adenocarcinoma cell lines, providing evidence for an attractive strategy against CRC.
Journal
|
STIM1 (Stromal Interaction Molecule 1)
8d
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer (clinicaltrials.gov)
P2, N=48, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2024 --> Feb 2025
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
|
RAS wild-type
|
Opdivo (nivolumab) • Cabometyx (cabozantinib tablet)
8d
RECC-EV: A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer (clinicaltrials.gov)
P=N/A, N=40, Recruiting, University Hospital, Bordeaux | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
Trial completion date • Trial primary completion date • Liquid biopsy • Biopsy
8d
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer (clinicaltrials.gov)
P1, N=10, Completed, Emory University | Active, not recruiting --> Completed
Trial completion • Combination therapy
|
CD8 (cluster of differentiation 8)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • pepinemab (VX15)
8d
Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer (clinicaltrials.gov)
P1/2, N=24, Recruiting, Sun Yat-sen University | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF wild-type
|
Erbitux (cetuximab) • capecitabine
8d
Enrollment open • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • SMAD4 (SMAD family member 4)
|
KRAS mutation • BRAF mutation • NRAS mutation • BRAF wild-type • SMAD4 mutation
|
Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Enweida (envafolimab)
8d
Identification and analysis of prognostic metabolic characteristics in colon adenocarcinoma. (PubMed, Heliyon)
Finally, the investigation of variations in immune infiltration and the analysis of relevant biological pathways validate the prognostic significance of the independent post-factors within this molecular model. This research aims to provide references for comprehending the mechanism of post-transcriptional regulation of COAD and molecular therapy.
Journal
|
FABP7 (Fatty Acid Binding Protein 7) • MMP1 (Matrix metallopeptidase 1) • ACOX1 (Acyl-CoA Oxidase 1)
8d
Development of rice bran-derived nanoparticles with excellent anti-cancer activity and their application for peritoneal dissemination. (PubMed, J Nanobiotechnology)
These results indicated that rbNPs are promising nanoparticles, hold significant potential for anti-cancer applications, and are expected to play a vital role in cancer treatment.
Journal
|
CCND1 (Cyclin D1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
|
CCND1 expression
|
pegylated liposomal doxorubicin
8d
Integrative multi-omics characterization reveals sex differences in glioblastoma. (PubMed, Biol Sex Differ)
Collectively, our study provides unprecedented insights into the fundamental modulators of tumor progression and clinical outcomes between male and female GBM patients and facilitates sex-specific treatment interventions. Highlights Female GBM patients were characterized by increased MGMT promoter methylation and favorable clinical outcomes compared to male patients. Female GBMs exhibited higher levels of genomic instability, including aneuploidy and TMB. Each sex-specific GBM is characterized by unique pathway dysregulations and molecular subtypes. EGFR activation is prevalent in male patients, while female patients are marked by SPP1 hyperphosphorylation.
Journal • Tumor mutational burden
|
EGFR (Epidermal growth factor receptor) • TMB (Tumor Mutational Burden) • MGMT (6-O-methylguanine-DNA methyltransferase) • SPP1 (Secreted Phosphoprotein 1)
|
MGMT promoter methylation
9d
Ring Finger 43 Hot-spot Frameshift Mutation G659V in Colorectal Cancer Patients: Report from a Tertiary Cancer Care Hospital in North India. (PubMed, Int J Appl Basic Med Res)
To the best of our knowledge, this is the first study from North India to show the involvement of RNF43 p.G659fs variant in CRC patients. The mutation correlated with MMR protein deficiency and seems to be conferring tumorigenicity independent of the Wnt pathway.
Journal
|
RNF43 (Ring Finger Protein 43)
|
RNF43 mutation • RNF43 G659fs
10d
ASPIRIN Trial Belgium (clinicaltrials.gov)
P3, N=148, Active, not recruiting, University Hospital, Antwerp | Recruiting --> Active, not recruiting | N=400 --> 148 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
10d
RELMA-C: Relapse Markers for Colorectal Cancer (clinicaltrials.gov)
P=N/A, N=264, Completed, Novigenix SA | Recruiting --> Completed | N=200 --> 264 | Trial primary completion date: Dec 2022 --> Dec 2023
Trial completion • Enrollment change • Trial primary completion date
10d
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer (clinicaltrials.gov)
P2, N=59, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting --> Active, not recruiting | N=96 --> 59 | Trial primary completion date: Feb 2025 --> May 2024
Enrollment closed • Enrollment change • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Opdivo (nivolumab) • relatlimab (BMS-986016)
11d
Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa (clinicaltrials.gov)
P=N/A, N=50, Terminated, Centre Hospitalier Universitaire de Nice | N=180 --> 50 | Unknown status --> Terminated; the tissue mass of each biopsy sample was not sufficient to perform an exploratory analysis to assess the level of expression of the P2RX7 protein.
Enrollment change • Trial termination
11d
New trial
11d
CENSURE: Stage II/III Colorectal Cancer Recurrence (clinicaltrials.gov)
P=N/A, N=400, Recruiting, City of Hope Medical Center
New trial
12d
Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development. (PubMed, Int J Mol Sci)
As a proof of concept, we identify two new, drug-like small molecules with the new method; these compounds specifically inhibit the growth of the PANC-1 cell line with KRAS mutation G12D in vitro and in vivo. Importantly, the two new compounds show significantly lower IC50 and higher specificity against the G12D KRAS mutant human pancreatic cancer cell line PANC-1, as compared to the recently described selective G12D KRAS inhibitor MRTX-1133.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus)
|
KRAS mutation • KRAS G12D • RAS mutation • KRAS G12
|
MRTX1133
14d
BARD1 deletion in a patient with suspected hereditary colorectal cancer. (PubMed, Hum Genome Var)
Here, we present the case of a 43-year-old female patient diagnosed with sigmoid colon adenocarcinoma whose maternal family members met the Amsterdam Criteria II for Lynch syndrome. Comprehensive multigene panel testing revealed a heterozygous BARD1 exon 3 deletion.
Journal • BRCA Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BARD1 (BRCA1 Associated RING Domain 1)
14d
Phase classification • Enrollment change • Combination therapy • Mismatch repair
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
Tyvyt (sintilimab) • IBI310 (ipilimumab biosimilar)
14d
Trial completion • Combination therapy • Metastases
|
MSI (Microsatellite instability) • CEACAM5 (CEA Cell Adhesion Molecule 5)
|
Tecentriq (atezolizumab) • Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • cibisatamab (RG7802)
15d
A comprehensive analysis of the prognostic and immunological role of ANK3 in pan-cancer. (PubMed, Transl Cancer Res)
ANK3 could serve as a new biomarker specific to prognosis and immunotherapy in various cancers. Our findings could contribute to the development of novel strategies for treating malignancies.
Journal • Tumor mutational burden • IO biomarker • Pan tumor
|
TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ANK3 (Ankyrin 3)
15d
Establishing a carcinoembryonic antigen-associated competitive endogenous RNA network and forecasting an important regulatory axis in colon adenocarcinoma patients. (PubMed, J Gastrointest Oncol)
Additionally, it may be related to ferroptosis, N6-methyladenosine (m6A) methylation, and tumor stemness and interfere with the sensitivity of tumor cells to 5-fluorouracil and immunotherapy. The LCMT1-AS2/RPS6KA5 axis may be instrumental in tumor progression, potentially acting as a prognostic biomarker and therapeutic target.
Journal • IO biomarker
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • RPS6 (Ribosomal Protein S6) • MIR454 (MicroRNA 454)
|
CEACAM5 expression
|
5-fluorouracil
15d
LncRNA PCAT6 is a predictor of poor prognosis of colorectal cancer. (PubMed, J Gastrointest Oncol)
The high expression of lncRNA PCAT6 in CRC cell lines was demonstrated by PCR experiments. PCAT6 represents a promising prognostic biomarker of poor CRC patient survival outcomes, with DNA methylation and RNA-mediated gene silencing being potentially promising mechanistic pathways whereby this lncRNA may shape patient outcomes.
Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • PCAT6 (Prostate Cancer Associated Transcript 6)
16d
Nanoparticles Synergize Ferroptosis and Cuproptosis to Potentiate Cancer Immunotherapy. (PubMed, Adv Sci (Weinh))
Here the design of a core-shell nanoparticle, CuP/Er, for the co-delivery of copper (Cu) and erastin (Er) to cancer cells for synergistic cuproptosis and ferroptosis is reported...Consequently, CuP/Er promotes proliferation and infiltration of T cells, and when combined with immune checkpoint blockade, effectively reinvigorates T cells to mediate the regression of murine colon adenocarcinoma and triple-negative breast cancer and prevent tumor metastasis. This study suggests a unique opportunity to synergize cuproptosis and ferroptosis with combination therapy nanoparticles to elicit strong antitumor effects and potentiate current cancer immunotherapies.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
erastin
16d
Focus on RAS Codon 61 Mutations in Metastatic Colorectal Cancer: A Retrospective Analysis. (PubMed, Cancers (Basel))
At a median follow up of 96.2 months, the median OS for codon 61 RAS-mutated patients was significantly shorter compared to RAS/BRAF wild-type (26.9 vs. 36.0 months, HR 0.56) patients, while no significant difference was observed compared to non-codon 61 RAS-mutated and BRAF V600E-mutated patients. We showed a negative prognostic impact and a statistically significant correlation between codon 61 RAS mutations and metastatic involvement of the peritoneum and ovary.
Retrospective data • Journal • Metastases
|
BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
|
BRAF V600E • BRAF V600 • BRAF wild-type • RAS mutation • RAS wild-type
16d
Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment (clinicaltrials.gov)
P1/2, N=80, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jul 2025 --> Dec 2024 | Trial primary completion date: Jul 2025 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression • CEACAM5 overexpression
|
Gazyva (obinutuzumab) • RG7827 • cibisatamab (RG7802)